Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3534-3544

  Prato, Sandro ^a,b   Zhan, Yifan ^a   Mintern, Justine D ^a,b   Villadangos, Jose A ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYCLOPHOSPHAMIDE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ERADICATION THERAPY; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; LYMPHOMA; MICE; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN;

EID: 84885121180     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300803     Document Type: Article

References (57)

1. Zhang, N., and M. J. Bevan. 2011. CD8 (+) T cells: foot soldiers of the immune system. Immunity 35:161-168.
2. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12:492-499.
3. Kim, P. S., and R. Ahmed. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22:223-230.
4. Akbar, A. N., and S. M. Henson. 2011. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat. Rev. Immunol. 11:289-295.
5. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
6. Fourcade, J., Z. Sun, M. Benallaoua, P. Guillaume, I. F. Luescher, C. Sander, J. M. Kirkwood, V. Kuchroo, and H. M. Zarour. 2010. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207:2175-2186.
7. Matsuzaki, J., S. Gnjatic, P. Mhawech-Fauceglia, A. Beck, A. Miller, T. Tsuji, C. Eppolito, F. Qian, S. Lele, P. Shrikant, et al. 2010. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 107:7875-7880.
8. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207:2187-2194.
9. Melief, C. J. 2008. Cancer immunotherapy by dendritic cells. Immunity 29:372-383.
10. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
11. Schumacher, T. N. 2002. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2:512-519.
12. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8:299-308.
13. Brenner, M. K., and H. E. Heslop. 2010. Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 22:251-257.
14. Quintarelli, C., G. Dotti, S. T. Hasan, B. De Angelis, V. Hoyos, S. Errichiello, M. Mims, L. Luciano, J. Shafer, A. M. Leen, et al. 2011. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 117:3353-3362.
15. Rosenberg, S. A. 2011. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 8:577-585.
16. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117:1466-1476.
17. Pascolo, S., N. Bervas, J. M. Ure, A. G. Smith, F. A. Lemonnier, and B. Pérarnau. 1997. HLA-A2.1-restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185:2043-2051.
18. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739-1742.
19. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17-27.
20. Hildner, K., B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, et al. 2008. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322:1097-1100.
21. Mueller, S. N., W. Heath, J. D. McLain, F. R. Carbone, and C. M. Jones. 2002. Characterization of two TCR transgenic mouse lines specific for herpes simplex virus. Immunol. Cell Biol. 80:156-163.
22. Parish, I. A., J. Waithman, G. M. Davey, G. T. Belz, J. D. Mintern, C. Kurts, R. M. Sutherland, F. R. Carbone, and W. R. Heath. 2009. Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance. Proc. Natl. Acad. Sci. USA 106:3901-3906.
23. Guillonneau, C., J. D. Mintern, F. X. Hubert, A. C. Hurt, G. S. Besra, S. Porcelli, I. G. Barr, P. C. Doherty, D. I. Godfrey, and S. J. Turner. 2009. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl. Acad. Sci. USA 106:3330-3335.
24. Vremec, D., J. Pooley, H. Hochrein, L. Wu, and K. Shortman. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164:2978-2986.
25. Henri, S., D. Vremec, A. Kamath, J. Waithman, S. Williams, C. Benoist, K. Burnham, S. Saeland, E. Handman, and K. Shortman. 2001. The dendritic cell populations of mouse lymph nodes. J. Immunol. 167:741-748.
26. Zhan, Y., Y. Zhang, D. Gray, E. M. Carrington, P. Bouillet, H. J. Ko, L. O'Reilly, I. P. Wicks, A. Strasser, and A. M. Lew. 2011. Defects in the Bcl-2-regulated apoptotic pathway lead to preferential increase of CD25 low Foxp3+ anergic CD4+ T cells. J. Immunol. 187:1566-1577.
27. Prato, S., J. D. Mintern, M. H. Lahoud, D. C. Huang, and J. A. Villadangos. 2011. Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. Immunol. Cell Biol. 89:595-603.
28. Villadangos, J. A., and P. Schnorrer. 2007. Intrinsic and cooperative antigenpresenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7:543-555.
29. Villadangos, J. A., and L. Young. 2008. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29:352-361.
30. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, et al. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849-1860.
31. Vremec, D., and K. Shortman. 1997. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J. Immunol. 159:565-573.
32. Wilson, N. S., D. El-Sukkari, G. T. Belz, C. M. Smith, R. J. Steptoe, W. R. Heath, K. Shortman, and J. A. Villadangos. 2003. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102:2187-2194.
33. Lin, M. L., Y. Zhan, J. A. Villadangos, and A. M. Lew. 2008. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol. Cell Biol. 86:353-362.
34. McDonnell, A. M., A. C. Prosser, I. van Bruggen, B. W. Robinson, and A. J. Currie. 2010. CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur. J. Immunol. 40:1617-1627.
35. Asano, K., A. Nabeyama, Y. Miyake, C. H. Qiu, A. Kurita, M. Tomura, O. Kanagawa, S. Fujii, and M. Tanaka. 2011. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34:85-95.
36. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704.
37. Griffith, T. S., and T. A. Ferguson. 2011. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity 35:456-466.
38. Du Page, M., C. Mazumdar, L. M. Schmidt, A. F. Cheung, and T. Jacks. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482:405-409.
39. Vacchelli, E., A. Eggermont, W. H. Fridman, J. Galon, E. Tartour, L. Zitvogel, G. Kroemer, and L. Galluzzi. 2013. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2:e24238.
40. Grupp, S. A., and C. H. June. 2011. Adoptive cellular therapy. Curr. Top. Microbiol. Immunol. 344:149-172.
41. Mueller, S. N., and R. Ahmed. 2009. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 106:8623-8628.
42. Zheng, Y., Y. Zha, G. Driessens, F. Locke, and T. F. Gajewski. 2012. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J. Exp. Med. 209:2157-2163.
43. Lu, B., and O. J. Finn. 2008. T-cell death and cancer immune tolerance. Cell Death Differ. 15:70-79.
44. Mrass, P., H. Takano, L. G. Ng, S. Daxini, M. O. Lasaro, A. Iparraguirre, L. L. Cavanagh, U. H. von Andrian, H. C. Ertl, P. G. Haydon, and W. Weninger. 2006. Random migration precedes stable target cell interactions of tumorinfiltrating T cells. J. Exp. Med. 203:2749-2761.
45. Boissonnas, A., L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena. 2007. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204:345-356.
46. Pittet, M. J., J. Grimm, C. R. Berger, T. Tamura, G. Wojtkiewicz, M. Nahrendorf, P. Romero, F. K. Swirski, and R. Weissleder. 2007. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc. Natl. Acad. Sci. USA 104:12457-12461.
47. Breart, B., F. Lemaître, S. Celli, and P. Bousso. 2008. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 118:1390-1397.
48. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439-5449.
49. Nagaraj, S., A. G. Schrum, H. I. Cho, E. Celis, and D. I. Gabrilovich. 2010. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184:3106-3116.
50. Engelhardt, J. J., B. Boldajipour, P. Beemiller, P. Pandurangi, C. Sorensen, Z. Werb, M. Egeblad, and M. F. Krummel. 2012. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21:402-417.
51. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck, and D. I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:828-835.
52. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233-4244.
53. Landsberg, J., J. Kohlmeyer, M. Renn, T. Bald, M. Rogava, M. Cron, M. Fatho, V. Lennerz, T. Wölfel, M. Hölzel, and T. Tüting. 2012. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-416.
54. Budhu, S., J. D. Loike, A. Pandolfi, S. Han, G. Catalano, A. Constantinescu, R. Clynes, and S. C. Silverstein. 2010. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. 207:223-235.
55. Amos, S. M., C. P. Duong, J. A. Westwood, D. S. Ritchie, R. P. Junghans, P. K. Darcy, and M. H. Kershaw. 2011. Autoimmunity associated with immunotherapy of cancer. Blood 118:499-509.
56. Woo, S. R., M. E. Turnis, M. V. Goldberg, J. Bankoti, M. Selby, C. J. Nirschl, M. L. Bettini, D. M. Gravano, P. Vogel, C. L. Liu, et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72:917-927.
57. Kenna, T. J., T. Waldie, A. McNally, M. Thomson, H. Yagita, R. Thomas, and R. J. Steptoe. 2010. Targeting antigen to diverse APCs inactivates memory CD8+ T cells without eliciting tissue-destructive effector function. J. Immunol. 184:598-606.